Bristol Myers Squibb (BMY) announced data from the cohorts of the KRYSTAL-1 study, evaluating the lung cancer drug Krazati (adagrasib) in combination with Erbitux (cetuximab), for the treatment of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC).KRYSTAL-1 is an open-label, multicenter, multiple expansion cohort phase I/II study to determine the safety and efficacy of Krazati in patients with advanced solid tumors that harbor a KRASG12C mutation.The pri ...

Bristol Myers Squibb (BMY) announced that the FDA approved a label expansion for chimeric antigen receptor (CAR) T cell immunotherapy Abecma. The therapy is now approved for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.It is to be noted that Abecma is being jointly developed and commercialized in the United States by Bristol My ...

April 6 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics.The drugmaker gained access to the treatment, called KarXT, through its $14 billion deal to buy Karuna Therapeutics last year. Long-term data of the drug reinforced the findings that were seen in previous short-term studies, the company sa ...

辉瑞（Pfizer） - 投资者可能在2024年第二季度市场动荡的开局中寻找四月份最被低估的生物科技股票，以获取更高的回报[1] - 辉瑞（Pfizer）是生物制药领域最大的公司之一，近年来经历了转型，更多地成为创新的生物科技公司，而不是依赖老药物的公司[4] - 辉瑞在2021年推出了突破性的COVID-19疫苗，但随着世界重新开放，疫苗需求急剧下降，公司股价也大幅下跌[5] - 辉瑞股票目前下跌超过52%，但对于愿意冒险的投资者来说，可能是一个有吸引力的深度价值选择[6] - 辉瑞的长期增长前景、最近收购的以癌症为重点的生物科技公司Seagen以及引人注目的药物管线都具有潜力，但在短期内扭转局势并不容易[7] - 辉瑞的股息率为6.17%，股价仅为销售额的2.6倍和未来市盈率的12.4倍，对于有耐心的投资者来说是一个值得考虑的选择[8] 百时美施贵宝（Bristol-Myers Squibb） - 百时美施贵宝（Bristol-Myers Squibb）是另一家成熟的生物制药公司，股价在过去一年中受到打击，但拥有一些有前景的新药，可能在中期内带来增长[10] - 百时美施贵宝最近在克罗恩病药物Zeposia的第三阶段临床试验中遭遇挫折，但公司的新药管线中还有其他有前景的候选药物[12] Moderna - Moderna是mRNA技术的创新者，虽然COVID-19疫苗业务可能不会回升，但公司正在创新，希望创造新的现金奶牛药物[13] - Moderna的mRNA技术和癌症疫苗的巨大潜力使其成为一个有吸引力的选择，但在公司恢复正收入增长之前，仍然是一个更具投机性的生物科技投资[15]

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this biopharmaceutical company have returned -2.3% over the past month versus the Zacks S&P 500 composite's +1.6% change. The Zacks Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, has lost 3.5% over this period. Now the key question is: Where could the stock be headed ...

Bristol Myers Squibb (BMY) announced that the European Commission (EC) has approved a label expansion of Reblozyl (luspatercept).The EC expanded the drug’s label to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS). The approval of Reblozyl covers all European Union (EU) member states.The latest approval is based on results of the late-stage COMMANDS study, wherein Reblozyl demonstrated superior eff ...

公司概况 - Bristol-Myers Squibb, Inc. (NYSE:BMY) 属于医疗保健部门和制药行业[1] 财务数据 - BMY 预计2024年的年度收入为458.5亿美元，每股收益为6.83美元，股息率为4.43%[1] 技术分析 - BMY 在过去几个月内出现了明显的下跌并且似乎已经进行了整理，类似于2019年和2012年之前的价格上涨[12] - 价格持续上涨，30周EMA趋势向上，可能是增加股票的信号[13] - 如果周PPO线穿过零线或中线，可能是增加股票的信号[13] - 如果价格和动量改善，重新测试2022年高位的$77不会让我感到惊讶[13]

医药和医疗保健领域表现 - 三家公司在医药和医疗保健领域表现出色，为投资者提供了巨大的增长机会[1] 公司一的战略业务发展 - 公司一通过战略业务发展活动支持其增长轨迹，不断专注于创新和满足未满足的医疗需求[2] 公司二的销售增长和盈利能力 - 公司二利用其药店知识在医疗保健行业实现强劲的销售增长和盈利能力，巩固了其作为英国顶级药店和零售品牌的声誉[3]

Bristol Myers (BMY) announced that a late-stage study on orally-administered Zeposia (ozanimod) in Crohn’s disease (CD) indication failed to achieve its primary endpoint.This late-stage study was the first of the two induction studies in the phase III YELLOWSTONE clinical program, which evaluated Zeposia in 600 adult patients with moderate to severe active CD over a 12-week treatment period. Initial results from the study showed that treatment with Zeposia failed to meet the primary endpoint of clinical rem ...

Biotech is an industry full of opportunity. It’s also known as one of the riskiest sectors to invest in. Why is this the case? Well, many of these companies are very small and focused on researching new drugs. These drugs, being their products, are thus in development and thus the future revenue is not assured. The future revenue hinges on successful FDA approvals and the ability to actually sell the drug. As such, this industry is known for companies that tank 50% in just days following poor clinical resul ...